{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:10:27Z","timestamp":1772777427061,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neo.2024.101053","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:14:26Z","timestamp":1725999266000},"page":"101053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A highly selective PI3K\u03b4 inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon"],"prefix":"10.1016","volume":"57","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huichen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeqin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-959X","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-9285","authenticated-orcid":false,"given":"Xiaomin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neo.2024.101053_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5583","key":"10.1016\/j.neo.2024.101053_bib0002","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"7011","key":"10.1016\/j.neo.2024.101053_bib0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/nature02991","article-title":"Essential role for the p110delta phosphoinositide 3-kinase in the allergic response","volume":"431","author":"Ali","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neo.2024.101053_bib0004","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/blood-2005-03-0944","article-title":"Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils","volume":"106","author":"Condliffe","year":"2005","journal-title":"Blood"},{"issue":"168","key":"10.1016\/j.neo.2024.101053_bib0005","doi-asserted-by":"crossref","first-page":"ra23","DOI":"10.1126\/scisignal.2001617","article-title":"PI3Kbeta plays a critical role in neutrophil activation by immune complexes","volume":"4","author":"Kulkarni","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neo.2024.101053_bib0006","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fimmu.2012.00224","article-title":"The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions","volume":"3","author":"Pauls","year":"2012","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.neo.2024.101053_bib0007","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.neo.2024.101053_bib0008","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/med.21341","article-title":"Targeting PI3Kdelta: emerging therapy for chronic lymphocytic leukemia and beyond","volume":"35","author":"Wei","year":"2015","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.neo.2024.101053_bib0009","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.neo.2024.101053_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.neo.2024.101053_bib0011","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.neo.2024.101053_bib0012","doi-asserted-by":"crossref","first-page":"233","DOI":"10.20524\/aog.2016.0022","article-title":"Idelalisib: a rare cause of enterocolitis","volume":"29","author":"Balagoni","year":"2016","journal-title":"Ann. Gastroenterol."},{"issue":"7505","key":"10.1016\/j.neo.2024.101053_bib0013","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neo.2024.101053_bib0014","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.4049\/jimmunol.1301533","article-title":"Innate PI3K p110delta regulates Th1\/Th17 development and microbiota-dependent colitis","volume":"192","author":"Steinbach","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.neo.2024.101053_bib0015","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1053\/j.gastro.2010.07.008","article-title":"Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta","volume":"139","author":"Uno","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neo.2024.101053_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1875397300903010022","article-title":"HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications","volume":"3","author":"Degorce","year":"2009","journal-title":"Curr. Chem. Genom."},{"issue":"6","key":"10.1016\/j.neo.2024.101053_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000934","article-title":"Epithelial p38alpha controls immune cell recruitment in the colonic mucosa","volume":"6","author":"Kang","year":"2010","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.neo.2024.101053_bib0018","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1016\/j.neo.2024.101053_bib0019","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","article-title":"PI3K induces B-cell development and regulates B cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.neo.2024.101053_bib0020","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1128\/MCB.22.24.8580-8591.2002","article-title":"Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex","volume":"22","author":"Jou","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"36","key":"10.1016\/j.neo.2024.101053_bib0021","doi-asserted-by":"crossref","first-page":"37651","DOI":"10.1074\/jbc.M311985200","article-title":"Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker","volume":"279","author":"Humphries","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neo.2024.101053_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2024.101053_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171221","article-title":"PI3Kdelta inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kdelta and BTK inhibitors","volume":"12","author":"Yahiaoui","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neo.2024.101053_bib0024","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/bjh.16118","article-title":"Single and combined BTK and PI3Kdelta inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas","volume":"187","author":"Spriano","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.neo.2024.101053_bib0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation phosphoinositide 3-kinase delta inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neo.2024.101053_bib0026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imm.13082","article-title":"Phosphoinositide 3-kinase delta is a regulatory T-cell target in cancer immunotherapy","volume":"157","author":"Lim","year":"2019","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.neo.2024.101053_bib0027","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2024.101053_bib0028","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: where we are and what comes next?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front. Immunol."},{"issue":"7911","key":"10.1016\/j.neo.2024.101053_bib0029","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3Kdelta inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neo.2024.101053_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.neo.2024.101053_bib0031","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines(R) insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.neo.2024.101053_bib0032","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3Kdelta inhibitor YY-20394 in patients with B-cell hematological malignancies","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2024.101053_bib0033","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10428194.2020.1832660","article-title":"Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)","volume":"62","author":"Coleman","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"15_suppl","key":"10.1016\/j.neo.2024.101053_bib0034","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1200\/JCO.2021.39.15_suppl.7550","article-title":"Efficacy and safety of the PI3K\u03b4 inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed\/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24)","volume":"39","author":"Pagel","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2024.101053_bib0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1470-2045(22)00333-3","article-title":"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial","volume":"23","author":"Pagel","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.neo.2024.101053_bib0036","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","article-title":"PI3K signalling in inflammation","volume":"1851","author":"Hawkins","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.neo.2024.101053_bib0037","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15698\/cst2021.04.246","article-title":"Roles of phosphatidyl inositol 3 kinase gamma (PI3Kgamma) in respiratory diseases","volume":"5","author":"Sala","year":"2021","journal-title":"Cell Stress."},{"issue":"10","key":"10.1016\/j.neo.2024.101053_bib0038","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020)","volume":"31","author":"Sabbah","year":"2021","journal-title":"Expert. Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.neo.2024.101053_bib0039","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.neo.2024.101053_bib0040","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3Kdelta\/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv."},{"issue":"15_suppl","key":"10.1016\/j.neo.2024.101053_bib0041","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2020.38.15_suppl.8016","article-title":"Tolerability and durable respones of the PI3K\u03b4 inhibitor ME-401 administered on an intermittent schedule in relapsed\/refractory (R\/R) follicular lymphoma (FL) and other B-cell malignancies","volume":"38","author":"Zelenetz","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.neo.2024.101053_bib0042","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.neo.2024.101053_bib0043","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.neo.2024.101053_bib0044","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-016-0436-2","article-title":"Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients","volume":"17","author":"Southworth","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.neo.2024.101053_bib0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.neo.2024.101053_bib0046","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (Parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-Kinase Delta (PI3Kdelta)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T03:07:41Z","timestamp":1729220861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"alternative-id":["S1476558624000952"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101053","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A highly selective PI3K\u03b4 inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101053"}}